Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)
NCT01121484
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Peri- and postmenopausal women aged 40 to 70 years who are fluent in both written and spoken English.
- Postmenopausal status defined by 12 consecutive months of spontaneous amenorrhea; less than 12 consecutive months with at least 6 consecutive months of spontaneous amenorrhea and a pre-baseline follicle-stimulating hormone (FSH) level >40 mIU/mL; or 6 months postsurgical bilateral oophorectomy (with or without hysterectomy). Perimenopausal women defined by the presence of any of the following within 6 months before baseline:
1. an absolute change of 7 days or more in menstrual cycle length within 6 months before baseline;
2. a change in menstrual flow amount (2 or more flow categories, eg, from light or moderately light to moderately heavy or heavy);
3. a change in duration (absolute change of 2 or more days); or
4. periods of amenorrhea lasting at least 3 months.
- A primary diagnosis of major depressive disorder (MDD) based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR), single or recurrent episode, without psychotic features using the modified Mini International Neuropsychiatric Interview (MINI).
- A Montgomery and Asberg Depression Rating Scale (MADRS) total score >=25 at the screening and baseline (day -1) visits and no more than a 5-point improvement from screening to baseline.
- Treatment with DVS SR (Pristiq®) at any time in the past and/or venlafaxine, ie,
Effexor® or Effexor XR®, 1 year prior to baseline.
- Treatment-resistant; eg, in the past 3 years if any of the following treatments have
failed: (a) 3 or more previous adequate trials of >=2 classes of antidepressant
medication, (b) electroconvulsive therapy, or (c) 2 adequate trials of psychotherapy
(eg, behavior therapy, behavior-marital therapy).
- History or current evidence of gastrointestinal disease known to interfere with the
absorption or excretion of drugs or a history of surgery known to interfere with the
absorption or excretion of drugs.
- Known presence of raised intraocular pressure or history of narrow-angle glaucoma.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Cairns, Queensland
- Everton Park, Queensland
- North Cairns, Queensland
- Box Hill, Victoria
- Heidelberg, Victoria
- West Heidelberg, Victoria
- West Perth, Western Australia
- Adana,
- Ankara,
- Diyarbakir,
- Istanbul,
- Izmir,
- Izmit,
- Malatya,
- Beverly Hills, California
- Burbank, California
- Encino, California
- Los Alamitos, California
- Newport Beach, California
- Northridge, California
- Orange, California
- Pasadena, California
- Upland, California
- South Miami, Florida
- St. Petersburg, Florida
- Edwardsville, Illinois
- Farmington Hills, Michigan
- Flint, Michigan
- Okemos, Michigan
- Clementon, New Jersey
- Dayton, Ohio
- Portland, Oregon
- Philadelphia, Pennsylvania
- Salt Lake City, Utah
- Seattle, Washington
- Brown Deer, Wisconsin
- Beverly Hills, California
- Encino, California
- Los Alamitos, California
- Orange, California
- Upland, California
- Aurora, Colorado
- Jacksonville, Florida
- South Miami, Florida
- St. Petersburg, Florida
- St. Petersburg, Florida
- Atlanta, Georgia
- Smyrna, Georgia
- Hoffman Estates, Illinois
- Rockville, Maryland
- New York, New York
- New York, New York
- Rochester, New York
- Dayton, Ohio
- Portland, Oregon
- San Antonio, Texas
- Seattle, Washington
- Edmonton, Alberta
- Medicine Hat, Alberta
- Kelowna, British Columbia
- Vancouver, British Columbia
- Bathurst, New Brunswick
- Burlington, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Gatineau, Quebec
- Pointe-Claire, Quebec
- Sherbrooke, Quebec
- Santiago,
- Santiago,
- Santiago,
- Medellin, Antioquia
- Barranquilla, Atlantico
- Bogota, Cundinamarca
- Bucamaranga, Santander
- Rijeka,
- Zagreb,
- Tallinn,
- Tallinn,
- Tartu,
- Voru,
- Vöru,
- Espoo,
- Helsinki,
- Joensuu,
- Kuopio,
- Seinajoki,
- Tampere,
- Turku,
- Caen,
- Dole,
- Douai,
- Orvault,
- Rennes,
- Liepaja,
- Sigulda,
- Sigulda,
- Strenci,
- Kaunas,
- Kaunas,
- Vilius,
- Vilnius,
- Vilnius,
- Vilnius,
- Skorzewo, Poznan
- Szczecin,
- Torun,
- Tuszyn,
- Wroclaw,
- Zuromin,
- Craiova, Dolj
- Brasov,
- Bucharest,
- Bucuresti,
- Bucuresti,
- Cluj Napoca,
- Bojnice,
- Bratislava,
- Liptovsky Mikulas,
- Michalovce,
- Rimavska Sobota,
- Trencin,
- Cape Town, Western Cape
- Durban,
- Paarl,
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364) | |||
| Official Title ICMJE | A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder | |||
| Brief Summary | A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of peri- and postmenopausal women with major depressive disorder | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 4 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
| Condition ICMJE | Major Depressive Disorder | |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE |
| |||
| Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 439 | |||
| Original Estimated Enrollment ICMJE | 400 | |||
| Actual Study Completion Date ICMJE | June 2011 | |||
| Actual Primary Completion Date | June 2011 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 40 Years to 70 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT01121484 | |||
| Other Study ID Numbers ICMJE | 3151A1-3364 B2061029 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | January 2012 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||